NCT01862536View on ClinicalTrials.gov

Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Pulmonary HypertensionChronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Tadalafil

Daily use of study drug to treat pulmonary hypertension.

DRUG

placebo

Daily use in double blind study.

Trial Locations (5)

30033

Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur

80220

VA Eastern Colorado Health Care System, Denver, CO, Denver

90073

VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles

02130

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston

02908

Providence VA Medical Center, Providence, RI, Providence

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT01862536 - Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease | Biotech Hunter | Biotech Hunter